Earnings summaries and quarterly performance for Verona Pharma.
Executive leadership at Verona Pharma.
Research analysts who have asked questions during Verona Pharma earnings calls.
Linda Tsai
Jefferies
5 questions for VRNA
Raghuram Selvaraju
H.C. Wainwright & Co.
5 questions for VRNA
Thomas Shrader
BTIG
5 questions for VRNA
Yasmeen Rahimi
Piper Sandler & Co.
5 questions for VRNA
Boobalan Pachaiyappan
ROTH Capital Partners
4 questions for VRNA
Joon Lee
Truist Securities
3 questions for VRNA
Tiago Fauth
Wells Fargo
3 questions for VRNA
Asim Rana
Truist Securities
2 questions for VRNA
Edward Thomason
Kempen & Co
2 questions for VRNA
Olivia Brayer
Cantor
2 questions for VRNA
Sushila Hernandez
Van Lanschot Kempen Investment Banking
2 questions for VRNA
Tara Bancroft
TD Cowen
2 questions for VRNA
Recent press releases and 8-K filings for VRNA.
- Verona Pharma plc shareholders have approved the proposed acquisition by Merck & Co., Inc..
- The acquisition is valued at $107 per American Depository Share (ADS), representing a total transaction value of approximately $10 billion.
- The transaction is expected to close on October 7, 2025, following the Court Hearing scheduled for October 6, 2025, to sanction the Scheme of Arrangement.
- At the Court Meeting, 99.49% in value of Scheme Shares voted in favor of the resolution to approve the Scheme.
- Verona Pharma reported that the launch of Ohtuvayre for COPD is progressing "remarkably well," with 55% penetration of Tier 1 prescribers and over 4,600 total prescribers in the first two quarters.
- Management stated they "don't object" to the consensus estimate of approximately $270 million in revenue for 2025.
- The company believes Ohtuvayre has the potential to achieve 5-10% market penetration in the US, with each 1% representing over $1 billion in revenue.
- Core patents for Ohtuvayre are expected to extend through the mid-2030s, with additional intellectual property potentially reaching into the 2040s.
- Verona Pharma reported a "remarkably well" launch for Ohtuvayre, described as the strongest ever in COPD, with growth in January and February 2025 exceeding Q4 2024.
- The company has achieved 4,600+ writers and reached 55% of Tier 1 prescribers in the first two quarters of launch.
- Management does not object to the consensus revenue estimate of approximately $270 million for 2025 and expects refills to be a key growth driver, with potential for significant market penetration where 1% equals over $1 billion in revenue.
- Pipeline updates include a Phase II trial for non-CF bronchiectasis expected to read out in late 2026 or early 2027, and a dose-ranging study for a combination product (ensifentrine + glycopyrrolate) starting in H2 2025.
- Ohtuvayre has patent protection through the mid-2030s (2035), with additional intellectual property extending into the 2040s.
Quarterly earnings call transcripts for Verona Pharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more